Taskapan H, Mahdavi S, Bellasi A, Martin S, Kuvadia S, Patel A
Clin Kidney J. 2024; 17(7):sfae188.
PMID: 39070948
PMC: 11273220.
DOI: 10.1093/ckj/sfae188.
Wang Y, Liu J, Fang Y, Zhou S, Liu X, Li Z
Front Endocrinol (Lausanne). 2024; 15:1400891.
PMID: 38974573
PMC: 11224516.
DOI: 10.3389/fendo.2024.1400891.
Udyavar N, Ahn J, Crepeau P, Morris-Wiseman L, Thompson V, Chen Y
Surgery. 2022; 173(1):111-116.
PMID: 36195501
PMC: 10443691.
DOI: 10.1016/j.surg.2022.05.040.
Raji Y, Ajayi S, Adeoye A, Amodu O, Tayo B, Salako B
Afr Health Sci. 2022; 22(1):344-351.
PMID: 36032486
PMC: 9382529.
DOI: 10.4314/ahs.v22i1.42.
Bouazza A, Tahar A, AitAbderrhmane S, Saidani M, Koceir E
Ren Fail. 2022; 44(1):1243-1262.
PMID: 35930297
PMC: 9359195.
DOI: 10.1080/0886022X.2022.2106244.
Oral Cholecalciferol Supplementation in Sahara Black People with Chronic Kidney Disease Modulates Cytokine Storm, Oxidative Stress Damage and Athero-Thromboembolic Risk.
Zoubiri H, Tahar A, AitAbderrhmane S, Saidani M, Koceir E
Nutrients. 2022; 14(11).
PMID: 35684085
PMC: 9182799.
DOI: 10.3390/nu14112285.
The Risk of Tuberculosis Infection in Non-dialysis Chronic Kidney Disease Patients.
Li C, Chen H, Chen W, Tu C, Hsia T, Hsu W
Front Med (Lausanne). 2021; 8:715010.
PMID: 34485344
PMC: 8409506.
DOI: 10.3389/fmed.2021.715010.
Racial differences in the relationship between high-normal 25-hydroxy vitamin d and parathyroid hormone levels in early stage chronic kidney disease.
Winder M, Mason D, Rangaswami J, Asif A, Vachharajani T, Mathew R
J Bras Nefrol. 2020; 43(1):34-40.
PMID: 33022030
PMC: 8061959.
DOI: 10.1590/2175-8239-JBN-2020-0138.
Race and Ethnicity Predict Bone Markers and Fracture in Pediatric Patients With Chronic Kidney Disease.
Laster M, Denburg M, Okuda Y, Kumar J, Furth S, Warady B
J Bone Miner Res. 2020; 36(2):298-304.
PMID: 32960469
PMC: 8893169.
DOI: 10.1002/jbmr.4182.
The Role of Vitamin D and Oxidative Stress in Chronic Kidney Disease.
Norris K, Olabisi O, Barnett M, Meng Y, Martins D, Obialo C
Int J Environ Res Public Health. 2018; 15(12).
PMID: 30513574
PMC: 6313656.
DOI: 10.3390/ijerph15122701.
Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis.
Laster M, Soohoo M, Streja E, Elashoff R, Jernigan S, Langman C
Pediatr Nephrol. 2018; 34(1):107-115.
PMID: 30267239
PMC: 6420309.
DOI: 10.1007/s00467-018-4048-6.
Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.
Jovanovich A, Kendrick J
Semin Nephrol. 2018; 38(4):397-409.
PMID: 30082059
PMC: 6615060.
DOI: 10.1016/j.semnephrol.2018.05.009.
Racial Variations in the Markers of Mineral Bone Disorders in CKD Patients in South Africa.
Waziri B, Duarte R, Dickens C, Dix Peek T, George J, Rekhviashvili V
Kidney Int Rep. 2018; 3(3):583-591.
PMID: 29854965
PMC: 5976813.
DOI: 10.1016/j.ekir.2017.12.004.
Development of Severe Hyperparathyroidism Despite Short-Term Renal Replacement Therapy.
Okada M, Tominaga Y, Hiramitsu T, Ichimori T
World J Surg. 2017; 42(2):425-430.
PMID: 28779382
DOI: 10.1007/s00268-017-4164-7.
Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society.
Norris K, Williams S, Rhee C, Nicholas S, Kovesdy C, Kalantar-Zadeh K
Semin Dial. 2017; 30(3):213-223.
PMID: 28281281
PMC: 5418094.
DOI: 10.1111/sdi.12589.
Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India.
Vikrant S, Parashar A
Indian J Endocrinol Metab. 2016; 20(4):460-7.
PMID: 27366711
PMC: 4911834.
DOI: 10.4103/2230-8210.183457.
Health care providers' support of patients' autonomy, phosphate medication adherence, race and gender in end stage renal disease.
Umeukeje E, Merighi J, Browne T, Wild M, Alsmaan H, Umanath K
J Behav Med. 2016; 39(6):1104-1114.
PMID: 27167227
PMC: 5512866.
DOI: 10.1007/s10865-016-9745-7.
Genetic African Ancestry and Markers of Mineral Metabolism in CKD.
Gutierrez O, Parsa A, Isakova T, Scialla J, Chen J, Flack J
Clin J Am Soc Nephrol. 2016; 11(4):653-62.
PMID: 26912553
PMC: 4822668.
DOI: 10.2215/CJN.08020715.
The Envy of Scholars: Applying the Lessons of the Framingham Heart Study to the Prevention of Chronic Kidney Disease.
Wasser W, Gil A, Skorecki K
Rambam Maimonides Med J. 2015; 6(3).
PMID: 26241225
PMC: 4524402.
DOI: 10.5041/RMMJ.10214.
Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Phan O, Maillard M, Malluche H, Stehle J, Funk F, Burnier M
Biomed Res Int. 2015; 2015:515606.
PMID: 26221597
PMC: 4499607.
DOI: 10.1155/2015/515606.